Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel)
in subjects with previously treated metastatic colorectal cancer. Subjects will be placed
into two separate cohorts based on their RAS mutation status.